PRICE TO BOOK: (0.97) PRICE TO SALES: 1."2"99_128_678,[ie:2] PRICE TO Liquidity: (4.75)
Enterprise Fwd Value / Revenue___PT 15, 0.005PriceTo
PRICE TO INT EXP: 1.684, 4.44M
PRICE TO Debt: 0.6, 12.5M
COST OF FUNDS: 36%
Return on Assets: (2196%)
MetricFwd: 0.09,on 83.956M
Weighted Price and Weighted Price Metric: 0.0700478,1.22
Notes on 84M: There are specific identifiable R&D expenses, CF Activity, Specific Financing Mechanisms, of 227M, that mgmt would most certainly want to convert to SALES going forward.....Inclusive of current MC of 7.478M.....
The reconcilement is rather difficult to explain, but expense rollfwd + previous 37M to current analysis, would equate to deficit less fwd value.....very,very close.....
You can put all the numbers and p/r crap you want in a post. The ONLY thing that can save ADLS from b/k is to find a way to get Restanza approved. That may not even do it, but without approval they have nothing. They cannot raise the needed money for 2 phase III superiority trials and even if they do the results are far from sure.
The other little bitty thing is they are pushing a drug that has little patent life left and will not by any means be a blockbuster so once they get the 600+ million shares out there won't be much left for the shareholders even with approval and good sales.
This company is dead money. You would be better off putting your cash under the mattress.